MiNK Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Its core products include agenT-797, an off-the-shelf, cryopreserved iNKT cell therapy designed for use without lymphodepletion or HLA matching, which enhances both innate and adaptive immunity by combining natural killer cell cytotoxicity with T cell memory response; MiNK-215, an IL-15 armored CAR-iNKT therapy targeting solid tumors such as metastatic colorectal cancer by eliminating fibroblast activation protein (FAP)-positive cancer-associated fibroblasts (CAFs); and next-generation engineered iNKT programs that include PRAME-TCR iNKTs targeting intracellular cancer antigens resistant to conventional treatments. The company manufactures these therapies at scale in Lexington, Massachusetts, and conducts clinical trials primarily targeting treatment-refractory solid tumors and immune disorders including graft-versus-host disease (GvHD) and severe pulmonary immune failure. Recent major changes at MiNK Therapeutics include the advancement of agenT-797 into Phase 2 clinical trials following promising clinical data demonstrating durable long-term remissions and immune reactivation in solid tumors resistant to checkpoint inhibitors; a strategic collaboration with Autonomous Therapeutics to combine MiNK’s iNKT platform with precision encrypted RNA technology targeting metastatic tumors; the receipt of significant non-dilutive grants from the U.S. Department of Defense for GvHD research; a $13 million equity financing round extending the company’s cash runway through mid-2026; and leadership expansion with expertise in pulmonary, trauma, and biodefense fields. The agency-led pipeline also includes new preclinical programs and aims to develop engineered bispecific iNKT cell engagers, enhancing the company's capacity to address solid tumors and immune diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, MiNK operates primarily in North America with ongoing clinical development activities. Its proprietary iNKT cell platform leverages scalable, off-the-shelf manufacturing to deliver universal cell therapies designed to provide transformational immune reconstitution. Target markets include patients with hard-to-treat cancers, immune-mediated diseases, and critical pulmonary conditions. MiNK reports a diversified pipeline encompassing native and engineered cellular immunotherapies optimized for durable tumor infiltration, immune modulation, and restoration of anti-tumor immunity. This strategic evolution positions MiNK Therapeutics as a pioneer in the emerging field of invariant natural killer T cell therapies, aiming to redefine treatment paradigms for cancers unresponsive to current immunotherapies and expanding into significant immune and inflammatory disease sectors. The company’s latest clinical data, collaborations, and financing achievements underpin its commitment to developing first- or best-in-class therapies with broad therapeutic potential and global applicability.
Company News
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics Q2 Earnings Call Highlights
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold” by Brokerages
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum